1. Medtech Insight
  2. >>Device Area
  3. >>Cardiology

Boston Scientific Pulse Field Ablation System Meets Clinical Endpoints For Persistent AF

Patients Able To Discontinue Use Of Anti-arrhythmic Drugs Following PFA Treatment

 
• By Natasha Barrow

Boston Scientific's Farapulse Pulsed Field Ablation System achieved safety and effectiveness endpoints in the ADVANTAGE AF clinical trial for the treatment of persistent atrial fibrillation, supporting “the paradigm shift to pulse-field ablation,” said Vivek Reddy, director of electrophysiology at Mount Sinai Fuster Heart Hospital.

Cardiology
(Shutterstock)

Data from the first phase of Boston Scientific’s ADVANTAGE AF clinical trial “further supports the paradigm shift to pulse-field ablation as a treatment for patients who are living with persistent and other complex forms of atrial fibrillation,” said Vivek Reddy, director of electrophysiology at New York’s Mount Sinai Fuster Heart Hospital. Reddy, who was the principal investigator for ADVANTAGE AF, presented the late-breaking data at AF Symposium 2025 in Boston.

“In addition to the positive safety and efficacy outcomes achieved in the ADVANTAGE AF study, a significant number of patients...

Welcome to Medtech Insight

Create an account to read this article

Already a subscriber?

More from Cardiology

Injuries And Deaths Linked To Boston Scientific Cardiac Devices. Company Responds

 
• By Brian Bossetta

The US FDA issued a pair of early alerts on Wednesday warning customers about serious adverse events associated with two Boston Scientific cardiac devices. Both alerts include numerous reports of injuries and deaths and are part of the FDA’s ongoing pilot to enhance its recall process.

Ultromics Wins $55M, The Key To Success: Diagnosing Diseases With Available Treatment

 
• By Natasha Barrow

Ultromics has secured $55m in Series C funding to advance its AI tool, EchoGo, which detects undiagnosed heart failure. The company's focus on diseases with available treatments resonated with investors.

Boston Scientific Raises Outlook … Again: Headwinds Offset By EP And Watchman

 
• By Natasha Barrow

Agent drug coated balloon, Watchman product sales, and electrophysiology (EP) business unit growth offset Acurate discontinuation and tariff headwinds. CEO Michael Mahoney shouted out coronary therapies business and answered questions on CMS proposed Ambulatory Surgical Center codes.

Injuries And Deaths Linked To Baxter Infusion Pump

 
• By Brian Bossetta

The US FDA says Baxter has notified customers about an issue with its Novum IQ Syringe Pump that is linked to two deaths and multiple injuries.

More from Market Intelligence

AvaSure, Oracle And NVIDIA Launch Virtual Care Assistant For Enhanced Clinical Workflow

 
• By Natasha Barrow

AvaSure’s new in-hospital virtual care assistant utilizes Oracle's cloud platform and NVIDIA AI software packages to improve clinical workflow by grading patients’ responses to a question format.

Prostate Cancer Research Urges UK To Implement Screening Program Without Delay

 
• By Natasha Barrow

Implementing a reflex test alongside traditional prostate cancer screening is cost-effective for high-risk groups, claims Prostate Cancer Research. Oxford BioDynamics sheds light on UK market conditions influencing the adoption of its reflex test, EpiSwitch PSE.

Philips Partners With Three Health Insurance Providers To Remotely Monitor High-Risk Pregnancies

 
• By Natasha Barrow

Several counties in the US state of Georgia are maternity care “deserts.” Remote monitoring of high-risk pregnancies with maternal hypertension and diabetes could help improve the state’s high rate of maternal mortality, according to leading health service provider Philips.